Procter & Gamble Health Limited
NSE: PGHLMarket Closed • NSE
Day range
52 week range
Procter & Gamble Health Limited closed at INR5200.00 (+0.99%) on volume 0.65x its 20-day average, trading 25.45% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +21.9% QoQ
2026-08-27
DIVIDEND Announced
Dividend - Rs 45 Per Share
2026-02-12
DIVIDEND Announced
Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 1.06x over last 3 years
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 1.77x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 27 Aug 2026 | Dividend | ₹45.00 / share | — | 27 Aug 2026 |
| 12 Feb 2026 | Dividend | ₹110.00 / share | — | 12 Feb 2026 |
| 22 Aug 2025 | Dividend | ₹45.00 / share | — | 22 Aug 2025 |
| 21 Feb 2025 | Dividend | ₹80.00 / share | — | 21 Feb 2025 |
| — | Dividend | ₹60.00 / share | — | 28 Nov 2024 |
| 14 Feb 2024 | Dividend | ₹50.00 / share | — | 14 Feb 2024 |
| — | Dividend | ₹50.00 / share | — | 23 Nov 2023 |
| 13 Feb 2023 | Dividend | ₹45.00 / share | — | 13 Feb 2023 |
| — | Dividend | ₹11.50 / share | — | 15 Nov 2022 |
| 13 May 2022 | Dividend | ₹41.00 / share | — | 12 May 2022 |
| — | Dividend | ₹40.00 / share | — | 02 Nov 2021 |
| — | Dividend | ₹42.00 / share | — | 18 Nov 2020 |
| — | Dividend | ₹416.00 / share | — | 23 May 2019 |
| — | Dividend | ₹15.00 / share | — | 21 May 2018 |
| — | Dividend | ₹11.00 / share | — | 25 May 2017 |
| — | Dividend | ₹7.50 / share | — | 22 Apr 2016 |
| — | Dividend | ₹6.00 / share | — | 30 Mar 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
IndiaHealthcare
Is Procter & Gamble Health Limited Shariah compliant?
Procter & Gamble Health Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.11%) complies with AAOIFI threshold (≤ 33%).
What is Procter & Gamble Health Limited's current valuation relative to peers?
Procter & Gamble Health Limited trades at a P/E of 24.2x compared to the sector median of 37x, and a Price-to-Book of 16.5x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 1.77x. Interest coverage is 787.4x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.